cisplatin + ifosfamide + vinorelbine

This is a combination chemotherapy regimen consisting of three cytotoxic agents—cisplatin, ifosfamide, and vinorelbine—used primarily in the treatment of advanced or inoperable non-small cell lung cancer (NSCLC). Each component has a distinct mechanism of action: - **Cisplatin** is a platinum-based alkylating agent that crosslinks DNA strands by binding to purine bases, leading to DNA damage and apoptosis. - **Ifosfamide** is an oxazaphosphorine alkylating agent that requires hepatic activation; it forms DNA crosslinks resulting in inhibition of DNA synthesis and function. - **Vinorelbine** is a semi-synthetic vinca alkaloid that inhibits microtubule polymerization by binding tubulin, disrupting mitotic spindle formation during cell division. The combination exploits different mechanisms to maximize antitumor efficacy. Clinical studies have shown this regimen can achieve objective response rates around 40% with manageable toxicity profiles in patients with advanced NSCLC[1][2][3].

Other names

cisplatin, ifosfamide, and vinorelbine combination chemotherapy